Navigating Adjuvant Melanoma Treatment Choices - European Medical Journal

Navigating Adjuvant Melanoma Treatment Choices

The EMJ Podcast | Bonus Episode

Dr Teresa Amaral and Prof Mario Mandalà discuss: The typical patient for whom adjuvant therapy may be considered, and provide details on therapy choices. The long-term advantages of adjuvant treatments, and prospects for the use of biomarkers to help elucidate the best candidates for such therapies. The potential disadvantages of adjuvant therapy, and how more studies are needed to understand if these therapies can impact quality of life and fertility.

Spotify | Apple | Amazon MusicDownload MP3 (31:51 mins)

This content was fully funded by Novartis Pharma AG

Speakers

Teresa Amaral

Skin Cancer Clinical Trials Center, Eberhard Karls University of Tübingen, Germany

Mario Mandalà

Università degli Studi di Perugia, Italy

Dr Teresa Amaral and Prof Mario Mandalà discuss:

  • The typical patient for whom adjuvant therapy may be considered, and provide details on therapy choices.
  • The long-term advantages of adjuvant treatments, and prospects for the use of biomarkers to help elucidate the best candidates for such therapies.
  • The potential disadvantages of adjuvant therapy, and how more studies are needed to understand if these therapies can impact quality of life and fertility.
Read more from the ‘Adjuvant Melanoma Treatment’ series: EMJ Dermatology 12 [Supplement 1] 2024 – European Medical Journal (emjreviews.com)

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.